touchCONGRESS Advancing the treatment of MDS and AML: An update from ASH 2021

In this interview, Prof. Pierre Fenaux answers the following questions:

• What have we learned about targeting specific mutations in MDS, and how will this impact the treatment landscape in the future?
• Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice?
• What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future?
• Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice?
• What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML who are unfit for intensive chemotherapy?

Prof. Pierre Fenaux is Head of the Hematology Department of Saint-Louis Hospital, Robert Debré Hospital and Avicenne Hospital (belonging to Assistance Publique-Hôpitaux de Paris Hospital network), and Professor of Hematology at the University of Paris, France. He is also part of the Inserm research unit n° 944 at Hôpital St Louis, Paris, with regards to his laboratory research. read more

Prof. Pierre Fenaux discloses: Honoraria and research grants from Abbvie, BMS, Janssen, Jazz and Novartis.

In this interview, Dr Esther Oliva answers the following questions:

• What have we learned about targeting specific mutations in MDS, and how will this impact the treatment landscape in the future?
• Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice?
• What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future?
• Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice?
• What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML who are unfit for intensive chemotherapy?

Dr Esther Oliva is Associate Professor of Blood Diseases, Oncology and Rheumatology, and leads the MDS, aplastic anaemia and anaemia section of the Hematology Unit at the Grande Ospedale Metropolitano in Reggio Calabria, Italy. read more

Dr Esther Oliva discloses: Advisory board fees from Alexion, Amgen, Celgene/BMS, Janssen and Novartis. Consultancy fees from Alexion and Celgene/BMS. Speaker fees from Amgen, Celgene/BMS and Novartis. Royalties from Celgene/BMS.

In this interview, Prof. Andrew Wei answers the following questions:

• What have we learned about targeting specific mutations in MDS, and how will this impact the treatment landscape in the future?
• Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice?
• What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future?
• Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice?
• What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML who are unfit for intensive chemotherapy?

Prof. Andrew Wei is an Adjunct Professor and Haematologist at the Alfred Hospital, and Metcalf Fellow at Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia. He leads the AML programme at the Alfred hospital as principal investigator, conducting clinical and translational research in AML. read more

Prof. Andrew Wei discloses: Advisory board/speakers bureau fees from Abbvie/Genentech, Amgen, Astellas, AstraZeneca, Celgene/BMS, Gilead, Janssen, MacroGenics, Novartis, Pfizer, Servier and Syndax. Consultancy fees from Astellas, Gilead, Janssen, Servier and Syndax. Honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Gilead, Janssen, MacroGenics, Novartis, Pfizer, Servier and Syndax. Research grants from Abbvie, Amgen, Astellas, Astex, AstraZeneca, Celgene/BMS, Genentech, Novartis, Servier and Syndax.

Prof. Wei is also an employee of the Walter and Eliza Hall Institute (WEHI) and is eligible for financial benefits associated with payments which WEHI receives in relation to venetoclax.